Three platform-technology deals paired Nanexa, Earendil Labs, and Atavistik Bio with Novo Nordisk, Genentech, and Roche to advance next-generation metabolic and oncology medicines.
|Articles|October 4, 2017
Lash Group Launches New Technology, Fusion
Advertisement
Lash Group-a part of AmerisourceBergen-announced the launch of its new patient support technology ecosystem, Fusion. Fusion is designed to combine technologies with workflows that are customized for patient support services. The technology has a proprietary data model for a personalized experience for patients, providers, and manufacturers.
Fusion was developed in collaboration with various technology partnerships and is designed to accelerate speed to therapy, improve patient and provider engagement, and generate actionable insights.
To learn more about Fusion, visit
Advertisement
Related to this article
Clinical data harmonization is the real bottleneck standing between life sciences companies and AI's transformative potential.
Regeneron and Sanofi expand their antibody alliance with four new drug candidates, FDA approves Camzyos for adolescents with obstructive hypertrophic cardiomyopathy, and Michael Abrams questions digital health's savings claims to employers.
FDA Approves Expanded Indication for Camzyos for Symptomatic Obstructive Hypertrophic Cardiomyopathy
FDA has expanded Camzyos's approval to treat symptomatic obstructive hypertrophic cardiomyopathy in pediatric patients as young as 12.
Regeneron and Sanofi are expanding their two-decade antibody alliance to co-develop four new long-acting immunology antibodies in a deal worth up to $8 billion.
Digital health's point-solution era is giving way to broader platforms, and the cost-savings claims those platforms make to employers often don't hold up to methodological scrutiny.
CORXEL’s Dr. Bo Liang on why efficacy is no longer obesity medicine's biggest gap — and the four unmet needs that define what comes next.
MRD Testing Is Becoming the Most Important Tool in Oncology Drug Development: Q&A with Eric Matthews
MRD testing is transforming oncology trials — compressing timelines, enriching populations, and generating earlier answers.
Advertisement
Advertisement
Trending on PharmExec
1
Regeneron and Sanofi Expand Antibody Alliance with Four New Drugs
2
The Next Chapter in Metabolic Drug Development
3
New U.S. Guidance Lays Out Exemptions for 100% Tariffs: Report
4
Novo Reports Real-World Data Showing Weight Loss After Switch to Oral Semaglutide Pill
5